|
1
|
Paez JG, Jänne PA, Lee JC, Tracy S,
Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et
al: EGFR mutations in lung cancer: Correlation with clinical
response to gefitinib therapy. Science. 304:1497–500.
2004.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Brooks DL, Wakefield L and Steeg P:
Abstract 4859: The role of LPAR1 and fibrosis in breast cancer
metastasis. Cancer Res. 77:4859. 2017.
|
|
3
|
Wang Y, Zhu B, Ye M and Chen Z: Study on
relationship between VEGF-C and lymphangiogenesis and lymph node
metastasis in non-small cell lung cancer. Zhongguo Fei Ai Za Zhi.
9:182–186. 2006.(In Chinese). PubMed/NCBI View Article : Google Scholar
|
|
4
|
Mok TS, Wu YL, Thongprasert S, Yang CH,
Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et
al: Gefitinib or carboplatin-paclitaxel in pulmonary
adenocarcinoma. N Engl J Med. 361:947–957. 2009.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Mitsudomi T, Morita S, Yatabe Y, Negoro S,
Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et
al: Gefitinib versus cisplatin plus docetaxel in patients with
non-small-cell lung cancer harbouring mutations of the epidermal
growth factor receptor (WJTOG3405): An open label, randomised phase
3 trial. Lancet Oncol. 11:121–128. 2010.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Zhou C, Wu YL, Chen G, Feng J, Liu XQ,
Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Erlotinib versus
chemotherapy as first-line treatment for patients with advanced
EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,
CTONG-0802): A multicentre, open-label, randomised, phase 3 study.
Lancet Oncol. 12:735–742. 2011.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Arrieta O, Campos-Parra AD, Zuloaga C,
Avilés A, Sánchez-Reyes R, Manríquez MEV, Covián-Molina E,
Martínez-Barrera L, Meneses A, Cardona A and Borbolla-Escoboza JR:
Clinical and pathological characteristics, outcome and mutational
profiles regarding non-small-cell lung cancer related to wood-smoke
exposure. J Thorac Oncol. 7:1228–1234. 2012.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Arrieta O, Cardona AF, Federico Bramuglia
G, Gallo A, Campos-Parra AD, Serrano S, Castro M, Avilés A, Amorin
E, Kirchuk R, et al: Genotyping non-small cell lung cancer (NSCLC)
in Latin America. J Thorac Oncol. 6:1955–1959. 2011.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Lee HJ, Kim YT, Kang CH, Zhao B, Tan Y,
Schwartz LH, Persigehl T, Jeon YK and Chung DH: Epidermal growth
factor receptor mutation in lung adenocarcinomas: Relationship with
CT characteristics and histologic subtypes. Radiology. 268:254–264.
2013.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Yamane H, Ochi N, Yasugi M, Tabayashi T,
Yamagishi T, Monobe Y, Hisamoto A, Kiura K and Takigawa N:
Docetaxel for non-small-cell lung cancer harboring the activated
EGFR mutation with T790M at initial presentation. Onco Targets
Ther. 6:155–160. 2013.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Rosell R, Moran T, Queralt C, Porta R,
Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M,
et al: Screening for epidermal growth factor receptor mutations in
lung cancer. N Engl J Med. 361:958–967. 2009.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Shigematsu H, Lin L, Takahashi T, Nomura
M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, et
al: Clinical and biological features associated with epidermal
growth factor receptor gene mutations in lung cancers. J Natl
Cancer Inst. 97:339–346. 2005.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Pallis AG, Voutsina A, Kalikaki A,
Souglakos J, Briasoulis E, Murray S, Koutsopoulos A, Tripaki M,
Stathopoulos E, Mavroudis D and Georgoulias V: ‘Classical’ but not
‘other’ mutations of EGFR kinase domain are associated with
clinical outcome in gefitinib-treated patients with non-small cell
lung cancer. Br J Cancer. 97:1560–1566. 2007.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Frega S, Lorenzi M, Fassan M, Indraccolo
S, Calabrese F, Favaretto A, Bonanno L, Polo V, Zago G, Lunardi F,
et al: Clinical features and treatment outcome of non-small cell
lung cancer (NSCLC) patients with uncommon or complex epidermal
growth factor receptor (EGFR) mutations. Oncotarget. 8:32626–32638.
2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Xu J, Jin B, Chu T, Dong X, Yang H, Zhang
Y, Wu D, Lou Y, Zhang X, Wang H and Han B: EGFR tyrosine kinase
inhibitor (TKI) in patients with advanced non-small cell lung
cancer (NSCLC) harboring uncommon EGFR mutations: A real-world
study in China. Lung Cancer. 96:87–92. 2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Chen D, Song Z and Cheng G: Clinical
efficacy of first-generation EGFR-TKIs in patients with advanced
non-small-cell lung cancer harboring EGFR exon 20 mutations. Onco
Targets Ther. 9:4181–4186. 2016.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Kuiper JL, Hashemi SMS, Thunnissen E,
Snijders PJF, Grünberg K, Bloemena E, Sie D, Postmus PE, Heideman
DA and Smit EF: Non-classic EGFR mutations in a cohort of Dutch
EGFR-mutated NSCLC patients and outcomes following EGFR-TKI
treatment. Br J Cancer. 115:1504–1512. 2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Zhou J and Ben S: Comparison of
therapeutic effects of EGFR-tyrosine kinase inhibitors on 19Del and
L858R mutations in advanced lung adenocarcinoma and effect on
cellular immune function. Thoracic Cancer. 9:228–233.
2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Li XY, Wu JZ, Cao HX, Ma R, Wu JQ, Zhong
YJ and Feng JF: Blockade of DNA methylation enhances the
therapeutic effect of gefitinib in non-small cell lung cancer
cells. Oncol Rep. 29:1975–1982. 2013.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Rahman S, Kondo N, Yoneda K, Takuwa T,
Hashimoto M, Orui H, Okumura Y, Tanaka F, Kumamoto K, Mostafa MG,
et al: Frequency of epidermal growth factor receptor mutations in
Bangladeshi patients with adenocarcinoma of the lung. Int J Clin
Oncol. 19:45–49. 2014.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Smits AJ, Kummer JA, Hinrichs JW, Herder
GJ, Scheidel-Jacobse KC, Jiwa NM, Ruijter TE, Nooijen PT,
Looijen-Salamon MG, Ligtenberg MJ, et al: EGFR and KRAS mutations
in lung carcinomas in the Dutch population: Increased EGFR mutation
frequency in malignant pleural effusion of lung adenocarcinoma.
Cell Oncol (Dodr). 35:189–196. 2012.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Zhou D: Detection of EGFR mutation by
DHPLC analysis in Chinese NSCLC and colorectal carcinoma patients
and its clinical implication. Oncol Prog, 2006.
|
|
23
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: The 7th edition of the AJCC Cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474.
2010.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Yoshida S, Miyata Y, Ohtsu A, Boku N,
Shirao K and Shimada Y: Significance of and problems in adopting
response evaluation criteria in solid tumor RECIST for assessing
anticancer effects of advanced gastric cancer. Gastric Cancer.
3:128–133. 2000.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Machnicki MM, Glodkowska-Mrowka E,
Lewandowski T, Ploski R, Wlodarski P and Stoklosa T: ARMS-PCR for
detection of BRAF V600E hotspot mutation in comparison with
Real-Time PCR-based techniques. Acta Biochim Pol. 60:57–64.
2013.PubMed/NCBI
|
|
26
|
Chu H, Zhong C, Xue G, Liang X, Wang J,
Liu Y, Zhao S, Zhou Q and Bi J: Direct sequencing and amplification
refractory mutation system for epidermal growth factor receptor
mutations in patients with non-small cell lung cancer. Oncol Rep.
30:2311–2315. 2013.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Ohsaki Y, Tanno S, Fujita Y, Toyoshima E,
Fujiuchi S, Nishigaki Y, Ishida S, Nagase A, Miyokawa N, Hirata S
and Kikuchi K: Epidermal growth factor receptor expression
correlates with poor prognosis in non-small cell lung cancer
patients with p53 overexpression. Oncol Rep. 7:603–610.
2000.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Nicholson RI, Gee JM and Harper ME: EGFR
and cancer prognosis. Eur J Cancer. 37 (Suppl 4):S9–S15.
2001.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, et al: Activating mutations in the
epidermal growth factor receptor underlying responsiveness of
non-small-cell lung cancer to gefitinib. N Engl J Med.
350:2129–2139. 2004.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Sharma SV, Bell DW, Settleman J and Haber
DA: Epidermal growth factor receptor mutations in lung cancer. Nat
Rev Cancer. 7:169–181. 2007.PubMed/NCBI View
Article : Google Scholar
|
|
31
|
Kobayashi S, Canepa HM, Bailey AS,
Nakayama S, Yamaguchi N, Goldstein MA, Huberman MS and Costa DB:
Compound EGFR mutations and response to EGFR tyrosine kinase
inhibitors. J Thorac Oncol. 8:45–51. 2013.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Wang S and Wang Z: EGFR mutations in
patients with non-small cell lung cancer from mainland China and
their relationships with clinicopathological features: A
meta-analysis. Int J Clin Exp Med. 7(1967)2014.PubMed/NCBI
|
|
33
|
Wu M, Zhao J, Song SW, Zhuo M, Wang X, Bai
H, Wang S, Yang L, An T, Zhang Y, et al: EGFR mutations are
associated with prognosis but not with the response to front-line
chemotherapy in the Chinese patients with advanced non-small cell
lung cancer. Lung Cancer. 67:343–347. 2010.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Sonobe M, Manabe T, Wada H and Tanaka F:
Mutations in the epidermal growth factor receptor gene are linked
to smoking-independent, lung adenocarcinoma. Br J Cancer.
93:355–363. 2005.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Yun CH, Boggon TJ, Li Y, Woo MS, Greulich
H, Meyerson M and Eck MJ: Structures of lung cancer-derived EGFR
mutants and inhibitor complexes: Mechanism of activation and
insights into differential inhibitor sensitivity. Cancer Cell.
11:217–227. 2007.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Chiu CH, Yang CT, Shih JY, Huang MS, Su
WC, Lai RS, Wang CC, Hsiao SH, Lin YC, Ho CL, et al: Epidermal
growth factor receptor tyrosine kinase inhibitor treatment response
in advanced lung adenocarcinomas with G719X/L861Q/S768I mutations.
J Thorac Oncol. 10:793–799. 2015.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Wu JY, Yu CJ, Chang YC, Yang CH, Shih JY
and Yang PC: Effectiveness of tyrosine kinase inhibitors on
‘uncommon’ epidermal growth factor receptor mutations of unknown
clinical significance in non-small cell lung cancer. Clin Cancer
Res. 17:3812–3821. 2011.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Mitsudomi T and Yatabe Y: Epidermal growth
factor receptor in relation to tumor development: EGFR gene and
cancer. FEBS J. 277:301–308. 2010.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Yoshida T, Ishii G, Goto K, Neri S,
Hashimoto H, Yoh K, Niho S, Umemura S, Matsumoto S, Ohmatsu H, et
al: Podoplanin-positive cancer-associated fibroblasts in the tumor
microenvironment induce primary resistance to EGFR-TKIs in lung
adenocarcinoma with EGFR mutation. Clin Cancer Res. 21:642–651.
2015.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Watanabe S, Minegishi Y, Yoshizawa H,
Maemondo M, Inoue A, Sugawara S, Isobe H, Harada M, Ishii Y, Gemma
A, et al: Effectiveness of gefitinib against non-small-cell lung
cancer with the uncommon EGFR mutations G719X and L861Q. J Thorac
Oncol. 9:189–194. 2014.PubMed/NCBI View Article : Google Scholar
|
